A5077150302- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Cutaneous lymphoproliferative disorders research
- Genetic factors in colorectal cancer
- Single-cell and spatial transcriptomics
- Medical Imaging Techniques and Applications
- Gene expression and cancer classification
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Cancer therapeutics and mechanisms
- Radiomics and Machine Learning in Medical Imaging
- Cancer-related molecular mechanisms research
- Cancer Mechanisms and Therapy
- Multiple Myeloma Research and Treatments
- Extracellular vesicles in disease
- Sarcoma Diagnosis and Treatment
- Molecular Biology Techniques and Applications
- Protein Degradation and Inhibitors
- Statistical Methods and Inference
- Statistical Distribution Estimation and Applications
- Acute Lymphoblastic Leukemia research
- Pericarditis and Cardiac Tamponade
- T-cell and Retrovirus Studies
Harvard University
2019-2021
Dana-Farber Cancer Institute
2006
EGFR is frequently mutated and amplified in lung adenocarcinomas sensitive to inhibitors gefitinib erlotinib. A secondary mutation, T790M, has been associated with acquired resistance but not shown be sufficient render mutant/amplified cancers resistant inhibitors. We created a model for studying by prolonged exposure of gefitinib-sensitive carcinoma cell line (H3255; amplified) vitro. The resulting T790M mutation small fraction the alleles that was undetected direct sequencing identified...
Abstract Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have heterogeneous outcomes; durable remissions are infrequently observed standard approaches. Circulating tumor DNA (ctDNA) assessment is a sensitive, potentially prognostic tool in this setting. We assessed baseline ctDNA to identify patients R/R DLBCL at high risk of relapse after receiving polatuzumab vedotin and bendamustine plus rituximab (BR) or BR alone. were transplant ineligible had received ≥1...
Single-cell RNA-sequencing technologies provide a powerful tool for systematic dissection of cellular heterogeneity. However, the prevalence dropout events imposes complications during data analysis and, despite numerous efforts from community, this challenge has yet to be solved. Here we present computational method, called RESCUE, mitigate problem by imputing gene expression levels using information other cells with similar patterns. Unlike existing methods, use an ensemble-based approach...
Abstract Background: Efbalropendekin alfa (EBA) is an engineered IL-15/IL-15Rα-Fc fusion protein with optimized potency, designed to improve systemic exposure and pharmacodynamics (PD) while decreasing acute toxicity. It aims enhance anti-tumor immunity via IL-15-mediated signaling on NK cells CD8+ T cells. This first-in-human study evaluated the safety, tolerability, pharmacokinetics (PK), PD, activity of EBA ± atezolizumab (ATZ) in Phase 1a (Ph 1a) Ph 1b. Methods: Patients (pts) aged ≥18...
Current radiological assessments of 18fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging data in diffuse large B-cell lymphoma (DLBCL) can be time consuming, do not yield real-time information regarding disease burden and organ involvement, hinder the use FDG-PET to potentially limit reliance on invasive procedures (e.g. bone marrow biopsy) for risk assessment. Our aim is enable assessment imaging-based factors at a scale we propose fully automatic artificial intelligence...
Background: Glofitamab is a T-cell-engaging bispecific antibody with novel 2:1 configuration that confers bivalency for CD20 (B cells) and monovalency CD3 (T cells). In an ongoing Phase I/II study (NCT03075696), glofitamab demonstrated durable complete responses (CR) favorable safety profile in patients (pts) R/R B-cell lymphomas (Phase I dose-escalation part; Hutchings, et al. 2021) pts DLBCL (pivotal II expansion). Aims: To evaluate tumor peripheral blood (PB) biomarkers associated...
7523 Background: the POLARIX study, pts with previously untreated DLBCL were randomized to Pola-R-CHP or R-CHOP (NCT03274492; Tilly et al. 2022). We validated prognostic value of ctDNA at baseline and after one cycle therapy in (Herrera 2022); here, we evaluate relationship between clearance PFS OS. Methods: Pts included if longitudinal results available. Plasma was measured baseline, Cycle (C) 5 Day (D) 1, end treatment (EOT), AVENIO NHL CAPP-Seq assay (Stokowski determined as described OS...
Abstract Aims Determining which patients with pericardial effusion require urgent intervention can be challenging. We sought to develop a novel, simple risk prediction score for effusion. Methods and results Adult admitted through the emergency department (ED) were retrospectively evaluated. The overall cohort was divided into derivation validation generation of novel using logistic regression. primary outcome drainage procedure or death attributed cardiac tamponade within 24 h ED arrival....
Introduction: In the POLARIX study, pts with previously untreated DLBCL were randomized to Pola-R-CHP or R-CHOP (NCT03274492; Tilly et al., 2022). We validated prognostic value of ctDNA at baseline and after one cycle therapy in (Herrera 2022); here, we evaluate relationship between clearance PFS OS. Methods: Pts included if longitudinal results available. Plasma was measured baseline, Cycle (C) 5 Day (D) 1, end treatment (EOT), AVENIO NHL CAPP-Seq assay (Stokowski al. determined as...
Abstract Classical simultaneous confidence bands for survival functions (i.e., Hall–Wellner, equal precision, and empirical likelihood bands) are derived from transformations of the asymptotic Brownian nature Nelson–Aalen or Kaplan–Meier estimators. Due to properties motion, a theoretical derivation highest density region cannot be obtained in closed form. Instead, we provide related optimization problem with local time processes. These can applied one-sample regarding both cumulative hazard...